Theravance Biopharma Inc (NASDAQ:TBPH) has been assigned a consensus rating of “Hold” from the seven research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $44.33.

TBPH has been the subject of a number of analyst reports. Zacks Investment Research upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating and set a $29.00 target price for the company in a research note on Monday, February 11th. BidaskClub upgraded shares of Theravance Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 10th. ValuEngine downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Tuesday, January 22nd. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $55.00 target price on shares of Theravance Biopharma in a research note on Friday.

In other Theravance Biopharma news, SVP Sharathchandra S. Hegde sold 9,033 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $24.71, for a total value of $223,205.43. Following the completion of the transaction, the senior vice president now owns 270,134 shares in the company, valued at $6,675,011.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TBPH. FNY Investment Advisers LLC acquired a new position in Theravance Biopharma in the fourth quarter valued at $42,000. Quantamental Technologies LLC purchased a new stake in shares of Theravance Biopharma in the fourth quarter valued at about $102,000. Amundi Pioneer Asset Management Inc. raised its holdings in shares of Theravance Biopharma by 34.1% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 5,500 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 1,400 shares during the last quarter. Citigroup Inc. raised its holdings in shares of Theravance Biopharma by 258.5% in the fourth quarter. Citigroup Inc. now owns 6,481 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 4,673 shares during the last quarter. Finally, United Services Automobile Association purchased a new stake in shares of Theravance Biopharma in the third quarter valued at about $210,000. Institutional investors own 84.94% of the company’s stock.

Shares of TBPH stock traded down $0.11 on Wednesday, reaching $23.38. 151,200 shares of the stock were exchanged, compared to its average volume of 208,647. The company has a market cap of $1.32 billion, a P/E ratio of -5.83 and a beta of 1.68. Theravance Biopharma has a twelve month low of $21.04 and a twelve month high of $35.48.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Featured Article: How are dividend achievers different from dividend aristocrats?

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.